Active surveillance with or without a 6 months Apalutamide treatment in low risk prostate cancer: a phase II randomized multicenter trial.
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Apalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 02 May 2017 Planned End Date changed from 27 Mar 2022 to 28 Apr 2022.
- 02 May 2017 Planned primary completion date changed from 27 Mar 2022 to 28 Apr 2022.
- 02 May 2017 Status changed from not yet recruiting to recruiting.